Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors
Authors:
- 1 December 2020
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 150, 178-185
Abstract
No abstract availableKeywords
Funding Information
- Science and Technology Commission of Shanghai Municipality (19411965900)
This publication has 29 references indexed in Scilit:
- Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: An overview of the literatureCancer Treatment Reviews, 2014
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)Journal of Thoracic Oncology, 2014
- Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor DimerizationCell, 2012
- 11 New response evaluation criteria in solid tumors: RECIST GUIDELINE VERSION 1.1European Journal of Cancer Supplements, 2009
- Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signalsCancer Letters, 2008
- Clinical Predictors of Metastatic Disease to the Brain from Non–Small Cell Lung Carcinoma: Primary Tumor Size, Cell Type, and Lymph Node MetastasesRadiology, 2007
- Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or ErlotinibClinical Cancer Research, 2006
- Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or ErlotinibClinical Cancer Research, 2006
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung CancersJNCI: Journal of the National Cancer Institute, 2005
- Identification of prognostic factors in patients with brain metastases: a review of 1292 patientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999